SCHEMBL26142007

SCHEMBL26142007

CC(C)c1ccc2ccc(=O)n(C)c2n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 2/20 0.41
CCND1 P24385 2/20 0.41
CCND2 P30279 2/20 0.41
CCND3 P30281 2/20 0.41
BRPF1 P55201 4/20 0.40
CA12 O43570 1/20 0.40
BRD4 O60885 1/20 0.40
CA9 Q16790 1/20 0.40
KAT2B Q92831 1/20 0.40
BRD9 Q9H8M2 1/20 0.40
MAPK8 P45983 1/20 0.36
MAPK9 P45984 1/20 0.36
MAPK10 P53779 1/20 0.36
HPGD P15428 2/20 0.35
LMNA P02545 2/20 0.35
TP53 P04637 1/20 0.35
TSHR P16473 1/20 0.35
HTT P42858 1/20 0.35
HSD17B10 Q99714 1/20 0.35
KMT2A Q03164 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19759418 0.73 DDB1 (0.37) KDM4E
SCHEMBL5364876 0.73 CDK4 (0.43) CDK4CCND1CCND2CCND3BRPF1
SCHEMBL21284819 0.70 CCR1 (0.45) CDK4CCND1CCND2CCND3BRPF1
SCHEMBL19231458 0.70 MTNR1A (0.46) CDK4CCND1CCND2CCND3BRPF1
SCHEMBL5701185 0.70 CDK4 (0.41) CDK4CCND1CCND2CCND3BRPF1
SCHEMBL21285447 0.69 PDE2A (0.31) KDM4E
SCHEMBL19231465 0.69 CDK4 (0.43) CDK4CCND1CCND2CCND3BRPF1
SCHEMBL19231460 0.69 CDC7 (0.44) CDK4CCND1CCND2CCND3BRPF1
SCHEMBL13153202 0.68 ALDH1A1 (0.51) LMNATSHRHTTKMT2AALDH1A1
SCHEMBL13941410 0.68 CDK4 (0.42) CDK4CCND1CCND2CCND3BRPF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230145003-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230145003-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB CDK4 1592/4885CCND1 4594/4885CCND2 4297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.